2nd Quarter 2019
Key topics in this quarter’s edition include:
- Tafamidis meglumine (Brand Name: Vyndaqel®), tafamidis (Brand Name: Vyndamax™): Treatment transthyretin-mediated amyloidosis cardiomyopathy (ATTR-CM)
- Golodirsen: Treatment of Duchenne muscular dystrophy
- Upadacitinib: Treatment of rheumatoid arthritis
- Oral semaglutide: Treatment of type 2 diabetes mellitus
Top